JOIN OUR USA EAST COAST 2018 STRATEGY MEETING
7th November 2018 | The Westin Boston Waterfront
OUR UNIQUE FORMAT
The Pharmacovigilance Roundtable Discussions Strategy Meeting is free to attend for qualified end-users. These include Senior Executives of Pharmacovigilance (from medium to large Pharma, Biopharma and Biotech players) as well as thought leaders from Academia and regulatory authorities.
Thought leaders who will benefit from attending include CXOs, EVPs, SVPs, VPs, Executive Directors, Directors and Global Heads responsible for:
– Pharmacovigilance, Risk Management, Drug Safety, Safety Surveillance, Clinical Safety, Patient Safety, Medical & Regulatory Affairs, Compliance, Post Authorisation Safety, Medical Safety, Epidemiology.
Fabio De GregorioVice President, Head, Drug Safety Europe, EU QPPV
Anders LindholmVP, Therapeutic Area Head, Inflammation & Immunology, Drug Safety
WHAT TO EXPECT
Interactive Roundtable Discussions
Attendees can proactively share and ask questions to their peers about the success of their work in an informal setting.
Director level one-to-one meetings
We provide opportunities to engage with one another in our strategy meeting in a series of pre-arranged business meetings by interacting face to face.
Tailor-fit and Personalized Agenda
Being able to experience different sessions is what makes our event unique that’s why our attendees can personalize and select sessions they want to participate in.
Several networking opportunities are in store for attendees to connect and build new relationships with their peers through luncheons, cocktails and informal introductions.
Thank you for reaching Proventa International
***The information you provided in this website is confidential and the company will strictly forbidden to share any part of these information with any third party without a written consent of the sender.
Our unique strategy meeting platform ensures that delegates can network with peers and benchmark their challenges whilst meeting a select number of supplier organizations that are currently at the forefront of innovation. This in turns helps them to save time and money associated in sourcing the best suppliers to procure solutions in an environment, which is 100% conducive to doing business.
If you are an exciting start-up trying to get your innovation in front global heads from the leading Pharmaceutical companies, or a mature market-leading conglomerate with legacy solutions trying to stay one step ahead of the competition – we are here to help!
WHAT PEOPLE SAY
Chief Information Officer
Its nice because they basically allowed people to engaged to discussions and questions. Academic and industry is very nice and informative
Ivan John Clement
Data Scientist - R&D
Its good because you really get the people to talk. They are willing to share their knowledge, the juniors are very eager to learn.
Manager Quality Assurance
The format is the beginning of breakthrough and integration, the level of delegates is very good and excellent, they learn a lot.
Founder & President
The kind of interaction is very interactive
Director & Professor
Because of diversity we really districts the points and all. People are very diversity and thoughtful in a round table.
Images coming soon
425 Summer St, Boston, MA 02210, USA
OUR MEDIA PARTNERS
Chief Medical Officer, SVP, Head of Global Medical Affairs, Global Patient Safety, Merck Professor, MERCK
Senior Vice President, Global Pharmacovigilance, Ipsen
Senior Vice President Head of Global Regulatory Affairs, Alexion Pharma
Martine is global head of regulatory affairs at Alexion Pharmaceuticals. She is based in Zurich,
Switzerland. She has over 20 years of combined R&D and global regulatory strategy
experience. She joined Alexion in 2009 and since then has been dedicated to the registration of
Orphan Medicinal Products globally as well as shaping a favorable regulatory environment for
orphan drug .
Throughout her career, Martine has been directly involved in multiple regulatory approvals
across the globe and most recently 2 enzyme replacement therapies for ultra-rare metabolic
Martine received her Pharm D from University Louis Pasteur in Strasbourg (France).
Vice President, Head Global Patient Safety - PV, MERCK
Fabio De Gregorio
Vice President, Head, Drug Safety Europe, EU QPPV
Prior to joining Shionogi in 2016, Fabio De Gregorio held various healthcare positions throughout Europe. Most recently, he worked with UBC (a pharmacovigilance service provider), in Geneva and London, and previously, as a QPPV and medical director with Tubilux Pharma S.p.A. in Rome, Italy. In addition to his 14 year experience in pharmacovigilance, he held positions as an associate ophthalmologist with Pannarale Ophthalmic Centre in Italy, and served as a post-graduate resident at different European ophthalmic centres, including Coimbra University (Portugal), Cantonal Hospital of Freiburg (Switzerland), and Barraquer Institute of Barcelona (Spain). Fabio De Gregorio is a GMC registered physician. He specialized in Ophthalmology and earned a PhD in patho-physiology of ocular microcirculation from the University “La Sapienza” of Rome.
Vice President Regulatory Affairs & Head of RA EMEA, Astellas Pharma
Vice President Global Regulatory Affairs, Santen
Global Head Medical & Clinical Drug Safety, Vifor Pharma
Mircea Ciuca, MD is Head of Medical & Clinical Drug Safety at Vifor Pharma in Switzerland. He is leading a team of scientists and physicians involved in all aspects of pharmacovigilance. Dr. Ciuca has about 12 years experience in drug safety. Prior to joining Vifor Pharma he held various positions (Deputy QPPV, Senior Pharmacovigilance Medical Manager, Drug Safety Advisor) at large pharmaceutical companies in The Netherlands, after successfully establishing and leading the medical-scientific department of a medium-sized CRO in Rotterdam. He graduated from the University of Medicine and Pharmacy in Bucharest Romania. He specialized in Emergency Medicine and later in Obstetrics & Gynecology. He was involved in clinical practice and academic teaching for about 12 years.
VP, Therapeutic Area Head, Inflammation & Immunology, Drug Safety
Anders received his MD at the Karolinska Institute in Stockholm, from which he also earned a PhD in Clinical Pharmacology and Transplantation Surgery. He practiced as a transplantation surgeon in Sweden. His scientific production includes more than 80 publications in peer reviewed journals. Subsequent to the academic career, Anders spent six years at Novo Nordisk as a Clinical Leader leading successful filings for a rapid acting insulin analogue. For the last 15 years Anders has been TA Safety Head at J&J, Shire and Celgene providing oversight for a department of physicians and scientists developing safety evaluations, benefit-risk assessments, and RMPs.